A5034443008- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Protein Tyrosine Phosphatases
- SARS-CoV-2 and COVID-19 Research
- Nail Diseases and Treatments
- T-cell and Retrovirus Studies
- Phagocytosis and Immune Regulation
- Heart Failure Treatment and Management
- Peptidase Inhibition and Analysis
- CNS Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Cardiac Imaging and Diagnostics
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Erythropoietin and Anemia Treatment
- Ultrasound and Hyperthermia Applications
- Cardiac electrophysiology and arrhythmias
Centre Hospitalier du Mans
2019-2024
Centre Hospitalier Victor Dupouy
2002
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare aggressive most reported in Asia. We performed comprehensive clinical, pathological and genomic study of 71 European MEITL patients (36 males, 35 females, median age 67 years). The majority presented with gastrointestinal involvement had emergency surgery, 40% stage IV disease. tumors were morphologically classified into two groups: typical (58%) atypical (i.e., non-monomorphic or necrosis, angiotropism starry-sky...
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In VIALE-A study, was given until progression but there are no data on its optimal duration responding patients who do not tolerate indefinite therapy. We retrospectively analyzed outcome discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly diagnosed (ND) AML and 22 with morphological relapse refractory were included. ND cohort (n = 62), 28 stopped azacitidine 34...
Abstract Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) shown interesting results in this setting. However, little information is available about their efficacy combination. This multicenter retrospective study aimed to evaluate the safety of combination BBv patients noncutaneous R/R PTCL among 21 LYSA centers France Belgium. The primary objective was overall response rate. A total 82 were...
LBA7005 Background: Despite recent advances, there remains a need for novel therapies pts with R/R DLBCL. BV, an anti-CD30 antibody-drug conjugate, has shown efficacy and safety when combined lenalidomide (len) rituximab (R) in heavily pretreated populations (Bartlett 2022; Ward 2022). The double-blind, global phase 3 ECHELON-3 study (NCT04404283) compared BV R+len (R2) vs R2 DLBCL who are ineligible HSCT or CAR T-cell therapy. Here, we present results from the interim analysis (IA) overall...
This phase 2 study investigated pevonedistat + azacitidine venetoclax (n = 83) versus 81) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. The was stopped early following negative results from PANTHER, which evaluated higher-risk myelodysplastic syndromes/chronic myelomonocytic or low-blast AML. Outcomes were analyzed up to the datacut. For venetoclax, median follow-up 8.44 7.95 months; complete remission (CR) rate 45% 49%; composite CR...
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) untreated RT of diffuse large B-cell histology (NCT03931642). In this multicentre phase 2 study, without complete response (CR) two cycles were eligible to receive 8-week induction via continuous vein infusion stepwise...
The real-life retrospective observational study CARMYN aimed at investigating the long-term efficacy and safety of carfilzomib in combination with dexamethasone lenalidomide (KRd, 159 patients). These patients (62% first 38% second relapse, median age 62 yo) were treated between 02/2014 02/2017. Most had been pre-exposed to bortezomib (98.2%) an IMID (75.4%). At time collection, 90% permanently discontinued carfilzomib. Data collection was conducted from January July 2021 27 participating...
Background: CASSIOPEIA, a phase 3 trial of patients (pts) with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT), demonstrated significant improvement in stringent complete response rates post‐consolidation and progression‐free survival daratumumab, bortezomib, thalidomide, dexamethasone (D‐VTd) vs VTd alone induction/ASCT/consolidation (Part 1). Part 2 (maintenance) is ongoing. Aims: To utilize patient‐reported outcomes (PRO) assessments as tool...